OctoPlus announces agreement with a US biotechnology company on its controlled release technology
OctoPlus N.V. announced that it has signed an agreement with a US biotechnology company relating to the use of OctoPlus' controlled release technology.
Under the contract, OctoPlus will develop a controlled release version of a product currently in clinical development using its proprietary drug delivery technology PolyActive®. The client will reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement are not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

SRI spins off AI-powered drug discovery platform Synfini, Inc. - Synfini to commercialize and scale automated compound testing for rapid drug production
Category:Norwegian_mycologists
Intercell starts a Phase I clinical trial for a new Streptococcus pneumoniae vaccine - Study aims to obtain safety and immunogenicity data of this new vaccine candidate
AEterna Zentaris Announces Completion of Patient Enrollment for Ozarelix Phase II Trial in Benign Prostatic Hyperplasia
Structure of protective protein in the eye lens revealed - Heat shock proteins provide protection against cataracts

Acetate regulates immune cells for a precisely orchestrated immune defense - Similar to a pressure valve, which prevents the pressure from rising to critical levels, the regulation of immune cells by acetate prevents the immune reaction from overshooting
Congenital_absence_of_the_vas_deferens
Merck Intends to Submit Cladribine Tablets to Treat Multiple Sclerosis for Registration in Europe - Decision based on data available from the Cladribine Tablets clinical program and performed analyses
Decriminalization_of_non-medical_marijuana_in_the_United_States
Category:Pseudomonadales

Proscan elektronische Systeme GmbH - Graben, Germany
